» Articles » PMID: 32291726

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis

Overview
Date 2020 Apr 16
PMID 32291726
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: No willingness-to-pay (WTP) per quality-adjusted life-year (QALY) value exists for the Kingdom of Saudi Arabia (KSA).

Objective: The primary objective of this study was to determine the WTP for a QALY in the KSA.

Methods: Adult citizens of the KSA, patients with cancer, or members of the general public (MGP) were recruited to participate in a time trade-off survey to elicit health utilities. Cancer was chosen as the disease of interest for patients and the MGP, with a scenario describing stage 3 colorectal cancer, because it is a disease condition that impacts on both quality of life and survival time. In a second step, respondents were asked about their WTP to move from the estimated health state to a state of perfect health for 1 year (QALY). Finally, that amount was processed to generate the WTP for a full QALY. The second step was repeated with a 5-year horizon. Sensitivity analyses were performed without outliers.

Results: From 400 participants, data from 378 subjects were obtained and usable: 177 patients, 201 MGP; 278 male, 100 female subjects; 231 aged 26-65 years. Demographic distribution varied widely between the two subgroups for age, education level, and employment status, but with less variation in sex and income. Elicited health utilities were 0.413 (0.472 after adjustment) for the overall group, 0.316 (0.416) for patients, and 0.499 (0.508) for MGP. Overall WTP for a QALY was $US25,600 (adjusted $US32,000) for the 1-year horizon and $US19,200 (adjusted $US22,720) for the 5-year horizon.

Conclusion: This was the first empirical attempt to estimate the WTP per QALY for the KSA. Results are comparable to those in some other countries and to gross domestic product figures for the KSA. Further research in a country-wide sample is warranted.

Citing Articles

Quality of life for patients on oncology treatments in the Kingdom of Saudi Arabia: a systematic review.

Althemery A, Alzahrani R, Alajlan N, Alrajhi A J Pharm Policy Pract. 2025; 18(1):2449036.

PMID: 39811823 PMC: 11731331. DOI: 10.1080/20523211.2024.2449036.


Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.

Tran B, Tran T, La N, Nguyen T, Nguyen M, Huynh T Asian Pac J Cancer Prev. 2024; 25(5):1725-1735.

PMID: 38809645 PMC: 11318811. DOI: 10.31557/APJCP.2024.25.5.1725.


Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.

Huang L, Peng X, Sun L, Zhang D Cost Eff Resour Alloc. 2023; 21(1):37.

PMID: 37277820 PMC: 10243056. DOI: 10.1186/s12962-023-00442-y.


Determination of a cost-effectiveness threshold for cancer interventions in Iran.

Safari H, Poder T, Afshari S, Nahvijou A, Arab-Zozani M, Moradi N Front Oncol. 2022; 12:1039589.

PMID: 36578935 PMC: 9791211. DOI: 10.3389/fonc.2022.1039589.


Methodological Approaches to Cost-Effectiveness Analysis in Saudi Arabia: What Can We Learn? A Systematic Review.

Maraiki F, Bazarbashi S, Scuffham P, Tuffaha H MDM Policy Pract. 2022; 7(1):23814683221086869.

PMID: 35647291 PMC: 9133871. DOI: 10.1177/23814683221086869.


References
1.
Giardina S, Pane B, Spinella G, Cafueri G, Corbo M, Brasseur P . An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011; 54(4):938-46. DOI: 10.1016/j.jvs.2011.03.264. View

2.
Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Mason H . Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law. 2011; 6(4):435-47. DOI: 10.1017/S1744133111000181. View

3.
Iskedjian M, Desjardins O, Piwko C, Bereza B, Jaszewski B, Einarson T . Willingness to pay for a treatment for pain in multiple sclerosis. Pharmacoeconomics. 2009; 27(2):149-58. DOI: 10.2165/00019053-200927020-00005. View

4.
Cameron D, Ubels J, Norstrom F . On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018; 11(1):1447828. PMC: 5930346. DOI: 10.1080/16549716.2018.1447828. View

5.
Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R . Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ. 2011; 13(2):145-56. DOI: 10.1007/s10198-010-0293-8. View